bs-2646R [Primary Antibody]
Lymphocyte Activation Gene 3 Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: Lymphocyte Activation Gene 3

Immunogen Range: 201-300/525


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 297596

Swiss Prot: Q5BK54

Source: KLH conjugated synthetic peptide derived from human Lymphocyte Activation Gene 3

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Lymphocyte-activation protein 3 (LAG-3), also known as CD223, belongs to the immunoglobulin superfamily and contains 4 extracellular Ig-like domains. LAG-3 binds to HLA class-II antigens and is involved in lymphocyte activation. It is found on the cell surface of activated NK and T-lymphocytes. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG-3 to CD4.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)
ICC(1:100-500)

Predicted Molecular Weight: 58


Cross Reactive Species: Human
Mouse

Predicted Cross Reactive Species: Rat
Cow
Pig
Horse
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Parodi, Alessia, et al. "CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes." Cancer Immunology, Immunotherapy (2013): 1-12.Read more>>
  • Parodi, Alessia, et al. "CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes." Cancer Immunology, Immunotherapy (2013): 1-12.Read more>>
  • Chen Y et al. Antitumor effects of the silencing of programmed cell death ligand 1 in colorectal cancer via immunoregulation. (2018) Oncol.Rep. Read more>>
  • Lin Liu. et al. Potential Applications of Dual Haptoglobin Expression in the Reclassification and Treatment of Hepatocellular Carcinoma. TRANSL RES. 2024 MayRead more>>
VALIDATION IMAGES

293T cell lysates probed with LAG-3 Polyclonal Antibody, Unconjugated (bs-2646R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.


K562 cell lysates probed with LAG-3 Polyclonal Antibody, Unconjugated (bs-2646R) at 1:300 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.